Gelteq - רווח נקי למניה אחת בשנים עשר החודשים האחרונים GELS

Gelteq Limited generates revenue by licensing gel drug delivery systems, collecting royalties from pharmaceutical behemoths. The YoY TTM growth in net income per share visualizes this efficiency, with the value stabilizing at 0.00. The monetization of intellectual property relies on patents for non-pill drug administration. High certification barriers and unique ingredient protection technologies create a robust market moat.
Gelteq - פילוחים אנליטיים ומדדי מפתח (GELS)

Investors assess asset quality through the dynamics of annual earnings per share, utilizing the EPS TTM annual growth rate to promptly identify changes in profitability without quarterly delays. A decline in this metric signals rising operating expenses, which for Gelteq Limited (GELS) logically reflects clinical trial costs in the absence of current commercial sales.